Review of low-dose-rate radiobiology for clinicians.
The use of therapeutic modalities that employ low-dose-rate (LDR) radiation is becoming increasingly prevalent in the clinic (eg, systemic targeted radiation therapy and brachytherapy). A natural tendency for radiation oncologists as they become familiar with these new therapies is to make predictions regarding efficacy and toxicity based on extrapolations from high-dose-rate radiobiology. If unfounded, these extrapolations could be misleading. This article discusses general principles of LDR radiobiology applicable to radioimmunotherapy.
Murtha
A D
AD
Departments of Radiation Oncology and Experimental Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada.
D017209:Apoptosis / Q000528:radiation effects; D002453:Cell Cycle / Q000528:radiation effects; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D000860:Hypoxia; D008433:Mathematics; D009369:Neoplasms / Q000532:radiotherapy*; D016499:Radioimmunotherapy; D011879:Radiotherapy Dosage / Q000592:standards*